Gn-RH agonists in breast and gynaecologic cancer treatment.
The effects of Gn-RH agonists in advanced breast cancer patients have been examined. In both pre- and postmenopausal women they produce pituitary gland desensitisation and a fall in circulating concentrations of LH and FSH. In premenopausal patients plasma progesterone and oestradiol levels fall to the castrate or postmenopausal range within 3-4 weeks. Tumour remissions have been observed in approximately 30% of premenopausal women and approximately 10% of postmenopausal patients. The mechanism of action of Gn-RH agonists is discussed and their use projected to other tumour types.
Nicholson
R I
RI
Tenovus Institute for Cancer Research, University of Wales, College of Medicine, Heath Park, Cardiff, U.K.
Walker
K J
KJ
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000503:physiopathology; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008593:Menopause; D051381:Rats; D011919:Rats, Inbred Strains
D017273:Goserelin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin